TECH Stock Might Rise Following the Leo Shipping Announcement
Bio-Techne begins to ship the Leo System - the next-generation high throughput simple western platform.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss.
Bio-Techne Stock Set to Benefit From Expansion of RNAscope Menu
TECH unveils the RNAscope Probes menu for human and mouse transcriptome to advance spatial biology.
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
TECH registers continued growth momentum across its Diagnostics & Spatial Biology segment.
Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Bio-Techne Corporation (NASDAQ:TECH ) Q2 2025 Earnings Conference Call February 5, 2025 9:00 AM ET Company Participants David Clair - Vice President-Investor Relations Kim Kelderman - President and Chief Executive Officer Jim Hippel - Executive Vice President and Chief Financial Officer Conference Call Participants Puneet Souda - Leerink Partners Dan Leonard - UBS Matt Larew - William Blair Catherine Schulte - Baird Dan Arias - Stifel Conor McNamara - RBC Patrick Donnelly - Citi Sung Ji Nam - Scotiabank Operator Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management's prepared remarks.
Techne (TECH) Tops Q2 Earnings and Revenue Estimates
Techne (TECH) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.40 per share a year ago.
TECH Gears Up to Report Q2 Earnings: Here's What to Expect
In the second quarter, Bio-Techne is expected to have witnessed the stabilization of large-pharma customers and an increase in biotech customers' ordering trends.
TECH Stock Might Rise From the Expansion of Designer Protein Portfolio
Bio-Techne launches AI-engineered designer proteins to advance cell therapy and regenerative medicine.
Bio-Techne Launches ESR1 Mutation Monitoring Assay: Stock to Gain?
TECH's Asuragen brand unveils a highly sensitive ESR1 mutation monitoring assay.
Should You Continue to Retain Bio-Techne Stock in Your Portfolio?
Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.
Techne (TECH) Up 2.2% Since Last Earnings Report: Can It Continue?
Techne (TECH) reported earnings 30 days ago. What's next for the stock?
